Drugs that contain Olaparib

1. Drug name - LYNPARZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7151102 ASTRAZENECA Phthalazinone derivatives
Apr, 2022

(4 months ago)

US7981889 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(2 years from now)

US7449464 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(2 years from now)

US8247416 ASTRAZENECA Phthalazinone derivative
Sep, 2028

(5 years from now)

CN102627611A ASTRAZENECA Polymorphic Substance Of 4-[3-(4-Cyclopropanecarbonyl-Piperazine-1-Carboxyl)-4-Fluoro-Benzyl]-2H-Phthalazine-1-One
Jan, 2016

(6 years ago)

CN1473154A ASTRAZENECA 2, 3-Phthalazinone Derivatives
Oct, 2021

(11 months ago)

CN100400518C ASTRAZENECA 2, 3-Phthalazinone Derivatives
Oct, 2021

(11 months ago)

CN1905864B ASTRAZENECA For Dna Damage Repair Inhibitors For Treating Cancer
Mar, 2024

(1 year, 5 months from now)

CN102107008B ASTRAZENECA Dna Damage Repair Inhibitor For The Treatment Of Cancer
Mar, 2024

(1 year, 5 months from now)

CN102107008A ASTRAZENECA Dna Damage Repair Inhibitor For Treatment Of Cancer
Mar, 2024

(1 year, 5 months from now)

CN1905864A ASTRAZENECA Dna Damage And Repair Inhibitor For Curing Cancer
Mar, 2024

(1 year, 5 months from now)

CN1788000A ASTRAZENECA Phthalazinone Derivatives
Mar, 2024

(1 year, 5 months from now)

CN1788000B ASTRAZENECA Phthalazine Ketone Derivatives
Mar, 2024

(1 year, 5 months from now)

CN101528714B ASTRAZENECA 4-[3-(4-Cyclopropanecarbonyl-Piperazine-1-Carbonyl Carbonyl)-4-Fluorin-Benzyl]-2H-Phthalazin-1-Polymorphic Substance Of Ketone
Oct, 2027

(5 years from now)

CN104649979A ASTRAZENECA 4-[3-(4-Cyclopropanecarbonyl-Piperazine-1-Carbonyl Carbonyl)-4-Fluorin-Benzyl]-2H-Phthalazin-1-Polymorphic Substance Of Ketone
Oct, 2027

(5 years from now)

CN101528714A ASTRAZENECA Polycrystalline Of 4-[3-(4-Cyclopropanecarbonyl-Piperazine-1-Carbonyl)-4-Fluoro-Benzyl]-2H-Phthalazin-1-One
Oct, 2027

(5 years from now)

CN104649979B ASTRAZENECA 4 - [4 - (3-Cyclopropanecarbonyl-Piperazine-1-Carbonyl) - 4-Fluoro-Benzyl] - 2H-Phthalazine-1-One Polymorph
Oct, 2027

(5 years from now)

IN245218B ASTRAZENECA Substituted Benzyl Phthalazinones
Oct, 2021

(11 months ago)

IN200300611P1 ASTRAZENECA Substituted Benzyl Phthalazinones
Oct, 2021

(11 months ago)

IN200503895P1 ASTRAZENECA Phthalazinone Derivatives
Aug, 2025

(2 years from now)

IN200901539P1 ASTRAZENECA Phthalazinone Derivatives
Mar, 2029

(6 years from now)

EP1330442B1 ASTRAZENECA Phthalazinone Derivatives
Oct, 2021

(11 months ago)

EP1330442A1 ASTRAZENECA Phthalazinone Derivatives
Oct, 2021

(11 months ago)

EP2305221A1 ASTRAZENECA Dna Damage Repair Inhibitors For Treatment Of Cancer
Nov, 2024

(2 years from now)

EP1684736B1 ASTRAZENECA Dna Damage Repair Inhibitors For Treatment Of Cancer
Nov, 2024

(2 years from now)

EP2305221B1 ASTRAZENECA Dna Damage Repair Inhibitors For Treatment Of Cancer
Nov, 2024

(2 years from now)

EP1684736A1 ASTRAZENECA Dna Damage Repair Inhibitors For Treatment Of Cancer
Nov, 2024

(2 years from now)

EP2064189A2 ASTRAZENECA Polymorphic Form Of 4-[3-(4-Cyclopropanecarbonyl-Piperazine-1-Carbonyl)-4-Fluoro-Benzyl]-2H-Phthalazin-1-One
Oct, 2027

(5 years from now)

EP2064189B1 ASTRAZENECA Polymorphic Form Of 4-[3-(4-Cyclopropanecarbonyl-Piperazine-1-Carbonyl)-4-Fluoro-Benzyl]-2H-Phthalazin-1-One
Oct, 2027

(5 years from now)

EP2824098B1 ASTRAZENECA Method For The Preparation Of 4-[3-(4-Cyclopropanecarbonyl- Piperazine-1-Carbonyl)-4-Fluoro-Benzyl]-2H-Phthalazin-1-One
Oct, 2027

(5 years from now)

EP2824098A1 ASTRAZENECA Method For The Preparation Of 4-[3-(4-Cyclopropanecarbonyl- Piperazine-1-Carbonyl)-4-Fluoro-Benzyl]-2H-Phthalazin-1-One
Oct, 2027

(5 years from now)

EP1633724B1 ASTRAZENECA Phthalazinone Derivatives
Mar, 2029

(6 years from now)

EP1633724A1 ASTRAZENECA Phthalazinone Derivatives
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9169235 ASTRAZENECA Phthalazinone derivatives Mar, 2024

(1 year, 5 months from now)

US8912187 ASTRAZENECA Phthalazinone derivatives Mar, 2024

(1 year, 5 months from now)

US9566276 ASTRAZENECA Phthalazinone derivatives Mar, 2024

(1 year, 5 months from now)

US8143241 ASTRAZENECA DNA damage repair inhibitors for treatment of cancer Aug, 2027

(4 years from now)

US8071579 ASTRAZENECA DNA damage repair inhibitors for the treatment of cancer Aug, 2027

(4 years from now)

US8475842 ASTRAZENECA Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Dec, 2029

(7 years from now)

US8859562 ASTRAZENECA Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer Aug, 2031

(8 years from now)

Treatment: Treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Treatment of brca mutated ovarian cancer using parp inhibitor; Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; maintenance treatment of brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; maintenance treatment of brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.